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SUMMARY
The purpose of this study was to evaluate the effect of cholestyramine and lovastatin, lipid-Iowering agents, upon egg
quality, reproductive performance, plasma lipids and egg yolk cholesterol levels of Shaver laying hens. Twenty-six-
weeks-old hens were fed basal diet without animal products containing 0.2% cholestyramine (COLl), 0.3%
cholestyramine (COL2) or 0.005% lovastatin (LOV) for 6 weeks. It was observed that the supplementation of the
drugs did not impair albumen and shell quality. Hen performance was not adversely affected, with the exception of the
significant reduction (p < 0.05) in egg weights. No significant changes were observed on plasma lipids, and egg yolk
cholesterol remained unchanged with the addition of the drugs.
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INTRODUCTION
C oncern about the relationship between dietaryfat and the development of atherosc1erosis hasled to many attempts to change egg lipid
composition. The quantity of saturated dietary fat has been
pointed out as being greatly responsible for the increase in
plasma cholesterol concentration, which is related to the
incidence of coronary heart disease". Although eggs contain
low proportion of saturated fat' and the contribution of dietary
cholesterol to the incidence of coronary heart disease is
subject to considerable debate, the high concentration of
cholesterol in the egg yolk has been highlighted in the last
decades and has caused restrictions to its consumption. Thus,
any feasible means of reducing cholesterol content of eggs
would be of interest to egg producers and consumers.
Many studies have dealt with the effects of genetic
selection and various dietary factors in layers feeds on egg
yolk cholesterol. However, reductions in egg cholesterol
levels have not reached significant values. Therefore, much
attention has been focused on the use of numerous
pharmacological agents in an attempt to lower the cholesterol
content of eggsS•6,13.19.30.
Cholestyramine, a bile acid sequestrant, is a
hypocholesterolemic drug that binds bile acids in the lumen
of the gut and enhances their excretiorr-". The effects of
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cholestyramine on plasma lipids were studied in mice'", rats"
and chicks". Singh" verified a decrease in egg cholesterol
content in laying hens by dietary cholestyramine.
Lovastatin is inc1uded in the group of the most potent
hypocholesterolemic agents. It acts as competitive inhibitor
of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
(HMG-CoA reductase), the rate-limiting enzyme in the
cholesterol biosynthetic pathway-". In laying hens, Elkin;
Rogler' found reduction in yolk cholesterol concentration by
using 0.0059% to 0,0265% dietary lovastatin, with a reported
maximum reduction of 15.3% in egg cholesterollevel. More
recently, Mori'ê reported a decrease of 12,1% in yolk
cholesterol by feeding 0.0015% lovastatin to hens. On the
other hand, Luhman et ai. I? did not report effects on the yolk
cholesterol concentration by the addition of 0.0035%
lovastatin to laying hen diet.
The objectives of the present study were to evaluate
the effects of cholestyramine and lovastatin added to animal
products-free diets upon egg quality, laying performance,
plasma lipids and egg yolk cholesterollevels of laying hens.
MATERIAL AND METHOD
Birds, Diets and Management
A total of 128 Shaver layers at 26 weeks of age were
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distributed into 16 replicates (four cages per replicate with two
birds per cage) and randomly assigned to each of the four
experimental diets (four replicates per treatment) for a period
of 6 weeks (spring and summer). Hens fed basal diet without
animal products (Tab. 1) were the control group (CON). This
basal diet was supplemented with 0.2% cholestyramine (COLl),
0.3% cholestyramine (COL2) or 0.005% lovastatin (LOV).
Feed and water were provided ad libitum and a
photoperiod of 16 hours per day was given. Basal diet met
a11nutrient requirements for laying hens". During the
experirnent, egg production and egg weight data were
recorded daily and feed consumption weekly. Average egg
production, egg weight, feed intake and feed conversion
(kilograms of feed consumed per dozen eggs and per kilogram
of eggs) were ca\culated for each replicate group.
Egg Quality
For the evaluation of the shell quality, the specific
gravity of 16 eggs per treatment (four per replicate) was
determined by the saline solutions method". Albumen quality
(Haugh units) was evaluated by a S-8400 Ames® micrometer.
Egg shells were individually weighed and egg shell thickness
was measured by a 25M-5 Ames® micrometer.
Plasma Lipids Analysis
At the end of the experimental period, 5 rnL of blood
was drawn from the brachial vein from 10 birds per treatment,
and collected in heparinized tubes. The birds were bled during
the moming period, immediately after oviposition, and each
sample was provided by blood from two birds. Plasma was
immediately separated by centrifugation for 10 min at 1,400
x g. Plasma triglyceride * and total cholesterol **were
determined by enzymatic-colorimetric methods (according to
the manufacturer's directions). Plasma samples were processed
by an autoanalyzer Technicon® model RA-100.
Sample Preparation and Yolk Cholesterol Analysis
At the termination of the experiment, four eggs were
randomly collected from each replicate. Eggs were weighed
and hard-cooked by immersion in boiling water for 5 mino
Yolks were individually weighed and were prepared by
pooling and blending four yolks per sample and then were
stored in freezer at -20°C.
About 0.1 g of pooled yolk samples was subjected to
direct saponification followed by extraction of the
unsaponificable fraction, according to Hamill; Soliman". The
organic phase was redissolved with ethanol before injection
into a HPLCI5. The HPLC apparatus consisted oftwo Model
• Sera-Pak® kit 6684/6687, Bayer Co., NY.
••Monotest® kit I 497456, Boehringer Mannheim Argentina S.A.
•••Shimadzu CO., Kyoto, Japan.
Table 1
Composition of the basal diet (São Paulo, 1999).
Ingredients Percentage
Corn
Soybean meal
Rice bran
Gluten meal
Wheat middling
DL-Methionine
Choline chloride (50%)
Salt
Limestone
Diealcium phosphate
Vitamin premix (*)
Trace mineral premix (**)
58.20
21.00
5.00
3.00
3.00
0.07
0.03
0.30
7.50
1.50
0.25
0.25
Calculated composition
ME, kcal/kg 2,710.00
CP 17.80
Methionine 0.33
Methionine and cystine 0.62
Calcium 3.35
Phosphorus, total (%) 0.62
Phosphorus, available (%) 0.41
(*) Vitamin premix provided lhe following per kilogram of feed: vitamin
A, 10,000UI; vitamin D3, 1,500U1; vitamin E, 10UI; vitamin K3, 2 mg;
riboflavin, 4.0 mg; vitamin B 12,0.08 mg; nicotinic acid, 20mg; pantotenic
acid, 10mg; antioxidant, 65 mg;
(**) Trace mineral premix provided in milligrams per kilogram offeed:
Fe, 60 mg; Cu, 4 mg; Zn, 40 mg; Mn, 65 mg; I, 0.8 mg; Co, 0.2 mg;
selenium, 0.1 mg.
LC-10AD pumps (Shimadzu®)*** and a Model Class-LC
10 version 1.40 modular system (Shimadzu®) equipped with
a Model SPD-lOA ultraviolet-visible spectrophotometric
detector (Shimadzu®). A 5 mm CLC-ODS (250 X 4,6 mm)
Shim-Pack® column was used with a 5 mm LC G-ODS (10
X 4 mm) Shim-pack® guard column. The solvent was an
isocratic mixture of acetonitrile and 2-propanol (3: 1) and
flowed at a rate of 1.0 rnL/min. Samples were injected with
a 20 rnL loop. The ultraviolet detector was set at 215 nm".
Statistical Analysis
Statistical analysis was performed using the one-
way ANOVA procedure ofthe SAS Instituteéand Duncan's
multiple range test was used to compare treatment means.
RESULTS AND DISCUSSION
Ren Performance
Both levels of cholestyrarnine (0.2% and 0.3%) used
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Table 2
Performance of laying hens fed diets supplemented with cholestyramine and lovastatin (São Paulo, 1995).
Feed Conversion
Kg of consumed feed perTreatments Egg Weight(g)
Egg production
(%)
Con
Col1
Col2
Lov
53.8± 0.2a'
53.1 ± 0.3b
52.8 ± 0.2b
52.6 ± 0.2b
88.0 ± 0.8a
90.4± 1.0a
89.5± 1.1a
90.9± 1.1a
Egg consumption
(g/hen/d) dozen eggs kg of eggs
87.5 ± 1.2a
90.7 ± 1.4ab
92.7 ± 1.5b
89.1±1.5ab
1.20 ± 0.02a 1.85 ± 0.03a
1.21 ± 0.02a 1.90 ± 0.04ab
1.25± 0.03a 1.97± 0.04b
1.18± 0.03a 1.87± 0.04ab
* Means ± SEM within columns with no common superscript differ significantly (p < 0.05).
Table 3
Egg quality from hens fed diets supplemented with cholestyramine and lovastatin (São Paulo, 1995).
Treatments Specific gravity Shell Weight Shell Thickness Haugh Unit(g) (%) (mm) (%)
Con 1.0893± 0.0013a• 5.20 ± 0.14a 9.36 ± 0.1 0.380 ± 0.006a 97.5 ± 1.3ab
Col1 1.0888 ± 0.0012a 5.01 ± 0.12a 9.30 ± 0.2 0.374 ± 0.007a 96.0 ± 1.2b
Col2 1.0903 ± 0.0012a 5.10 ± 0.11a 9.46 ± 0.1 0.383 ± 0.007a 96.5 ± i.o=
Lov 1.0910 ± 0.0009a 5.13±0.11a 9.51 ± 0.11a 0.385 ± 0.006a 99.6 ± 1.0a
* Means± SEMwithincolumnswith nocommonsuperscriptdiffersignificantly(p<0.05).
Table 4
Plasma triglyceride and total cholesterol concentrations of laying
hens fed diets supplemented with cholestyrarnine and lovastatin
(São Paulo, 1995).
Treatments
Triglyceride Total cholesterol
Percentage Percentage
(mg/dl) change** (mg/dL) change**
Con
Col1
Col2
Lov
1076 ± 103a* 86.2 ± 6.7a
1130 ± 110a +5.1 85.5 ± 6.7a -0.8
1057±157a -1.7 84.6±10.0a -1.9
915 ± 98a -14.9 77.5 ± 5.0a -10.1
* Means ± SEM within columns with no common superscript differ
significantly (p < 0.05);
** Percentage change in comparison to contrai graup (CON).
in this trial caused a significant reduction in egg weight, but
there was no alteration in egg production (Tab. 2). As noted
in Tab. 2, cholestyratnine at 0.2% (COL!) did not affect feed
consumption, agreeing with Ueda et af.28. However, 0.3%
cholestyratnine (COL2) resulted in a significant increase in
feed intake, resulting, consequently, in an adverse effect on
feed conversion expressed as kg of feed consumed per kg of
eggs (Tab. 2). Feed conversion, expressed as kg of feed
consumed per dozen eggs, was not different among treatments.
The reduction in egg weight (Tab. 2) observed by the
supplementation of 0.005% lovastatin (LOV) agrees with
Elkin; Rogler', who reported a decline in the egg and yolk
weights by 0.0124% and 0.0265% dietary lovastatin.
Table 5
Egg yolk cholesterol content, percentage change in comparison to control groups, yolk weight (g) and egg weight (g). (São Paulo, 1995).
Egg yolk cholesterol content
Yolk weight Egg weightTreatments Percentage Percentage(mg/yolk) change** (mg/g) change**
(g) (g)
Con 164.2 ± 4.4a' 12.3 ± 0.2a 13.3 ± 0.2a 53.5 ± 0.5a
Col1 184.3 ± 5.9b +12.2 12.8±0.3a +4.3 14.4 ± 0.2b 54.7 ± 0.5a
Col2 181.5±1.3b +10.5 12.9 ± 0.1a +4.5 14.1±0.1b 54.6 ± 0.3a
Lov 168.1 ± 5.3a +2.3 12.1 ± O.4a -1.8 13.9±0.2b 54.3 ± O.4a
*Means± SEMwithincolumnswith nocommonsuperscriptdiffersignificantly(p<0.05).
** Percentagechangeincomparisontocontrolgroup(CON).
However, Luhman et al,", who used 0.0035% lovastatin in
the diet of White Leghom hens did not observe influence of
the drug on egg weights. According to Naber et al,"; drugs
that lirnit hepatic lipogenesis would not affect egg production
due to the great lipogenic capacity of the liver to support
lipid synthesis for egg yolk formation.
Egg Quality
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Specific gravity, shell weight, shell thickness and
albumen quality of eggs obtained from hens fed diets containing
cholestyratnine or lovastatin did not differ from those laid by
hens fed the basal diet (Tab. 3). The birds fed LOV produced
eggs with albumen quality (Haugh unit) significantly higher
than COL! (Tab. 3). The absence ofundesirable effects on the
quality of the egg shell by the addition of lovastatin, agrees
with the studies of Luhman et ai. 17
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Plasma Lipids Concentrations
Plasma triglyceride (1,076 mg/dL) and cholesterol
concentrations (86.2 mg!dL) from CON (Tab. 4) were similar
to those reported by Elkin; Rogler', 1,231 mg!dL and 89.5
mg!dL, respectively, in hens fed control diet. However, Weiss
et a1.30, Luhman et al." and Moril8 reported higher values
for hen plasma lipids. Plasma triglyceride and total
cholesterol levels were not affected by COLl and COL2 in
hens fed animal products free diets (Tab. 4). Ueda et af.28
noted that the addition of 2 to 4% cholestyrarnine to chicks
fed a cholesterol-free diet did not affect serum cholesterol
concentration. The absence of effects observed with the use
of cholestyramine can be attributed to the compensatory
increase in cholesterol synthesis from acetate or mevalonate".
According to Naber" another factor responsible for the
inefficiency of cholestyramine would be the fact that bile
excretion does not represent a significant amount of
cholesterol elimination in this species, where the main
excretion route would be represented by the egg.
Lovastatin at 0.005% (LOV) showed a tendency to
reduce the average values for triglyceride (14.9%) and total
cholesterol (10.1%) relative to CON, but this reduction was
not statistically significant. However, Elkin; Rogler' reported
significant decreases in plasma lipids of hens fed diets
supplemented with 0.029% and 0.241 % lovastatin, and Mori"
found great reduction in triglycerides (38.5%) and cholesterol
(36.0%) by the addition of 0.00 1% lovastatin in the diet. The
lack of effect observed in the present experiment, by the addition
of 0.005% lovastatin, could be explained mainly by the lower
plasma lipid levels of these hens. Probably, the animal products-
free diet collaborated to these reduced values". Besides, such
differences could be also explained by the age of the birds':'",
and environrnental conditions.
Egg Cholesterol Content
The control group presented an average cholesterol
concentration of 164.2 mg/yolk, and when it was expressed
as milligrams per gram of yolk, 12.3 mg/g of yolk. In spite
of the fact that egg cholesterol content is usually expressed
as milligrams per yolk, or milligrams per egg, the use of
the unit mg/g yolk eliminates the influence of both yolk
and egg weight, being therefore more recommended. Thus,
the average cholesterol concentration from the CON group
approaches that found by Elkin; Rogler', 12.1 mg/g ofyolk
for the control group, by using the HPLC method. Beyer;
Jensen? and Jiang et al. 15, also using HPLC, reported average
cholesterol va1ues of 11.0 mg/g of yolk and 11.7 mg/g of
yolk, respectively, lower than those found in the present
work. Luhman et al. 17 reported an average cholesterol
content of 15.55 mg/g of yolk for the control group using
the enzymatic method. Usually published egg cholesterol
data present many divergences, due to different methods
used in its determination. Besides, such differences could
be due to diet composition'v", egg productionv", and age
of the birds 10.17. The HPLC method is the most recommended
to determine egg cholesterol content".
Hens fed cholestyramine (COLl and COL2) did not
differ from CON in yolk cholesterol concentration,
expressed as mg/g of yolk. These findings do not support
the observations of Singh", who observed reduction in the
cholesterol content by supplementing with 0.41 %, 0.83%
and 1.64% cholestyramine in laying hens diet. The
inefficacy of cholestyramine in reducing yolk cholesterol
can be explained by the capacity of the hens to synthesize
cholesterol surplus to the necessary for the deposition in
the egg'". Just a small amount ofthis cholesterol is secreted
as bile acid".
The reduced intestinal bile acid reabsorption
decreases the hepatic cholesterol, which, by regulatory
feedback mechanism, provides the elevation in endogenous
cholesterol". This could determine an increased cholesterol
excretion. Thus, it was observed a significant increase in
yolk cholesterol from hens fed 0.2% or 0.3% cholestyrarnine
(COLl and COL3) when it was expressed as mg/yolk, due
to the elevation in yolk weight (Tab. 5). Unfortunately, the
egg comprises the major pathway for such excretion",
increasing egg cholesterol content, as observed in the
present study. As a result of these factors, bile acid
sequestrants are not effective in the reduction of egg
cholesterol contento
The supplementation of 0.005% lovastatin (LOV)
did not affect yolk cholesterol concentration, either
expressed as mg/g of yolk or mg/yolk (Tab. 5). On the other
hand, Elkin; Rogler' and Mori 18 reported reductions of
11.6% and 12.1%, respectively, in the cholesterol content
of the yolk (mg/g) with the addition of 0.0265% and
0.0015% lovastatin in the diet.
According to Khan et al. 16 and Arad et al. I, reduction
in liver cholesterol and VLDL cholesterol contents
determined by lovastatin, would be just a consequence of a
considerable reduction in the esterified cholesterol, without
any effect on free cholesterollevels. Thus, the decrease of
the yolk cholesterol attained in the present work and in the
experiments of Naber et al. 21, Waldroup et al. 29 and Elkin;
Rogler", could probably be attributed only to reductions in
esterified cholesterol contento On the other hand, it is known
that about 21% of the yolk cholesterol is under the form of
esterified cholesterol". Therefore, the possibilities of egg
cholesterol reduction beyond this limit are, probably, very
remote.
Egg cholesterol remained unchanged with the
addition of cholesterol and lovastatin, at the dosage and period
of this study. The available studies suggest that only small
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reductions in yolk cholesterol content are possible.
Campaigns advised by scientific and public health
communities should be driven towards a better
comprehension of the population with regard to the real
nutritional value of eggs and the true role of dietary
cholesterol in the incidence of the cardiovascular diseases.
Eggs, being considered one of the most complete food, can
and should be inc1uded in the daily diet, as long as they take
part of a saturated and unsaturated fat well balanced diet.
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RESUMO
O presente trabalho teve por objetivo avaliar os efeitos da colestiramina e da lovastatina, drogas hipolipemizantes,
sobre a qualidade do ovo, desempenho das aves, teores de lípides plasmáticos e de colesterol na gema do ovo de
galinhas poedeiras Shaver. Aves com 26 semanas de idade receberam como alimentação dieta formulada sem ingredientes
de origem animal (COM) acrescida de colestiramina a 0,2% (COLl) e 0,3% (COL2) e lovastatina a 0,005% (LOV)
durante seis semanas. A adição das drogas não prejudicou a qualidade da casca e do albúmen dos ovos. De um modo geral,
o desempenho produtivo das aves não foi afetado, com exceção da redução observada no peso médio dos ovos. Não foram
observadas mudanças nos teores de lípides plasmáticos das aves e a concentração de colesterol na gema permaneceu
inalterada mediante a adição das drogas.
UNITERMOS: Colesterol; Colestirarnina; Lovastatina; Gema de Ovo; Galinhas.
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